NCT07770074Not yet recruiting
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
Real-World Evidence of Second-line Systematic Therapy With BRAF V600E Mutation-guided Dabrafenib + Trametinib or Mutation-agnostic Multi-targeted Tyrosine Kinase Inhibitors (MKIs) in Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC)
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- 4 Jan 2027
- Primary completion date
- 5 Jan 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Thyroid cancer
- NCT number
- NCT07770074
What you commit to
- Study type: Observational
- Planned participants: 200
- From 4 Jan 2027 to the primary completion date, 5 Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients participating in a blinded interventional clinical trial, or any open-label observational study involving D+T or MKI, during the study period.
- Other protocol-defined inclusion/exclusion criteria may apply.
Who the study is looking for
- Patients with a diagnosis of thyroid cancer.
- Patients with a pathological confirmation of differentiated thyroid cancer (DTC).
- Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date).
- Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.